| Don J Elazar, MD | |
|
214 East Main Street, Ste 200, Gallatin, TN 37066 | |
| (615) 206-9111 | |
| (615) 206-9212 |
| Full Name | Don J Elazar |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 214 East Main Street, Gallatin, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730370610 | NPI | - | NPPES |
| 3726901 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35261 (Tennessee) | Primary |
| Entity Name | State Of Tennessee |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487791315 PECOS PAC ID: 5698687077 Enrollment ID: O20031104000309 |
News Archive
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 1 days ago
| Entity Name | Old Hickory Psychiatric Assn Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376634907 PECOS PAC ID: 5890710271 Enrollment ID: O20051014000268 |
News Archive
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Don J Elazar, MD 695 Nashville Pike, #313, Gallatin, TN 37066 Ph: (615) 206-9111 | Don J Elazar, MD 214 East Main Street, Ste 200, Gallatin, TN 37066 Ph: (615) 206-9111 |
News Archive
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 1 days ago
Elizabeth Reagan Franco, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 555 Hartsville Pike, Gallatin, TN 37066 Phone: 615-328-8888 | |
Dr. Megan Elizabeth Mason, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 300 Steam Plant Rd, Suite 300, Gallatin, TN 37066 Phone: 615-230-8070 Fax: 615-989-4661 | |
Dr. John Mark Lambert, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1529 Hunt Club Blvd Ste 100, Gallatin, TN 37066 Phone: 615-206-8650 | |
Gladys R. Gregory, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1207 Churchill Dr, Gallatin, TN 37066 Phone: 615-339-7578 Fax: 615-230-5454 | |
Dr. Jessica Ford Douglas, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 332 Sumner Hall Drive, Gallatin, TN 37066 Phone: 615-460-4500 Fax: 615-460-4502 |